Xintian Pharmaceutical (002873.SZ) released its 2023 annual report. During the reporting period, the company achieved an operating income of 9...
According to the Zhitong Finance App, Xintian Pharmaceutical (002873.SZ) released its 2023 annual report. During the reporting period, the company achieved revenue of 954 million yuan, a year-on-year decrease of 12.29%. Net profit attributable to shareholders of listed companies was RMB 808.711 million, a year-on-year decrease of 27.48%. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 750.95 million yuan, a year-on-year decrease of 25.87%. Basic earnings per share were $0.3489. It is proposed to distribute a cash dividend of 0.70 yuan (tax included) for every 10 shares to all shareholders.
During the reporting period, the company strictly complied with the requirements of relevant regulations, revised and improved the existing basic system, and established a comprehensive, systematic and effective internal control management system guided by risk management and focusing on compliance management and supervision. At the same time, with reference to regulatory requirements, relevant systems such as sole directors carrying out their duties have been revised and improved in line with the company's actual situation, further promoting the standardized operation of the company's three meetings and one level.